For more cancer news, visit the Vanderbilt-Ingram Cancer Center website »
New details on the DNA-cutting activity of topoisomerase II, a target of anti-cancer drugs, could lead to better chemotherapeutic agents.
Investigators at Vanderbilt-Ingram Cancer Center and several other centers may be one step closer to finding out why some melanoma patients relapse after treatment with a promising new drug.
A protein involved in repairing DNA damage associated with gastric reflux may play a tumor suppressor role in the esophagus and could represent a target for therapies to combat esophageal cancer.